MX2012006401A - Proceso para preparar composiciones oftalmicas farmaceuticas. - Google Patents

Proceso para preparar composiciones oftalmicas farmaceuticas.

Info

Publication number
MX2012006401A
MX2012006401A MX2012006401A MX2012006401A MX2012006401A MX 2012006401 A MX2012006401 A MX 2012006401A MX 2012006401 A MX2012006401 A MX 2012006401A MX 2012006401 A MX2012006401 A MX 2012006401A MX 2012006401 A MX2012006401 A MX 2012006401A
Authority
MX
Mexico
Prior art keywords
preparing
slurry
compositions
carbonic anhydrase
anhydrase inhibitor
Prior art date
Application number
MX2012006401A
Other languages
English (en)
Inventor
Ashish Ashokrao Deshmukh
Shirishkumar Kulkarni
Pravin Meghrajji Bhutada
Sajeev Chandran
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2012006401A publication Critical patent/MX2012006401A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones oftálmicas farmacéuticas que comprenden ingrediente(s) activos como inhibidor de anhidrasa carbónica (CAl) o combinaciones y procesos para realizar dichas composiciones y el uso de estas composiciones en poblaciones de pacientes que incluyen poblaciones pediátricas. Un proceso para preparar una composición oftálmica que comprende un inhibidor de anhidrasa carbónica que comprende a) preparar una suspensión que comprende un inhibidor de anhidrasa carbónica y un surfactante; b) preparar una suspensión de polímero que comprende un polímero y agua; c) preparar una solución que comprende la tonicidad y agentes conservadores; d) mezclar la suspensión del polímero del paso b y la solución del paso c, para formar un concentrado del excipiente líquido y ajustar un pH; e) agregar la suspensión del paso a, al concentrado del excipiente líquido del paso d y mezclar para homogenizar; f) realizar mediante autoclave la mezcla del paso e; g) medir la mezcla del paso f, bajo condición aséptica.
MX2012006401A 2009-12-03 2010-12-02 Proceso para preparar composiciones oftalmicas farmaceuticas. MX2012006401A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1415KO2009 2009-12-03
PCT/IN2010/000784 WO2011067791A2 (en) 2009-12-03 2010-12-02 Process for preparing pharmaceutical ophthalmic compositions

Publications (1)

Publication Number Publication Date
MX2012006401A true MX2012006401A (es) 2012-07-10

Family

ID=44115377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006401A MX2012006401A (es) 2009-12-03 2010-12-02 Proceso para preparar composiciones oftalmicas farmaceuticas.

Country Status (6)

Country Link
US (1) US8614210B2 (es)
EP (1) EP2506878A2 (es)
JP (1) JP5558582B2 (es)
AU (1) AU2010325632B2 (es)
MX (1) MX2012006401A (es)
WO (1) WO2011067791A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013175285A1 (en) 2012-05-21 2013-11-28 Aurobindo Pharma Limited Process for preparing ophthalmic suspension of brinzolamde
WO2014057499A1 (en) 2012-10-11 2014-04-17 Indoco Remedies Limited A process for manufacturing sterile brinzolamide ophthalmic suspension
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
EA030535B1 (ru) * 2013-10-17 2018-08-31 Сентисс Фарма Прайвет Лимитед Не содержащий консерванта офтальмологический фармацевтический состав
WO2015068105A1 (en) * 2013-11-08 2015-05-14 Sentiss Pharma Private Limited An improved process for manufacturing sterile ophthalmic pharmaceutical suspensions
UA118576C2 (uk) * 2014-01-24 2019-02-11 Сентис Фарма Прайвет Лімітед Фармацевтична композиція, яка містить бринзоламід
PL407710A1 (pl) * 2014-03-28 2015-10-12 Instytut Farmaceutyczny Sposób wytwarzania preparatu kropli do oczu w postaci zawiesiny zawierającej brynzolamid i preparat wytworzony tym sposobem
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
NZ728131A (en) 2014-07-11 2017-09-29 Fujifilm Corp Aqueous ophthalmic composition
WO2016063184A1 (en) * 2014-10-20 2016-04-28 Sentiss Pharma Private Limited Ophthalmic solution
EP3511020B1 (en) * 2014-12-02 2021-01-20 Novartis AG Manufacture of surfactant-containing compositions
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US9119876B1 (en) 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
WO2020072979A1 (en) * 2018-10-04 2020-04-09 Miraki Innovation Think Tank Llc Slurry and solution compositions
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법
JP2024506384A (ja) * 2021-02-10 2024-02-13 イオリクス セラピューティクス，インコーポレーテッド ロフルミラストの眼科的送達方法
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
JP5080445B2 (ja) * 2005-04-13 2012-11-21 アボット ゲーエムベーハー ウント コー． カーゲー 超微粒子懸濁液及び超微粒子を穏やかに製造する方法並びにその使用
US20070077303A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions

Also Published As

Publication number Publication date
US20120283252A1 (en) 2012-11-08
WO2011067791A2 (en) 2011-06-09
AU2010325632A1 (en) 2012-06-21
JP5558582B2 (ja) 2014-07-23
WO2011067791A3 (en) 2011-09-09
US8614210B2 (en) 2013-12-24
JP2013512894A (ja) 2013-04-18
EP2506878A2 (en) 2012-10-10
AU2010325632B2 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MX2012006401A (es) Proceso para preparar composiciones oftalmicas farmaceuticas.
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
EA200971116A1 (ru) Способ желатинизации фиброина шелка с применением обработки ультразвуком
MY143795A (en) Tetrahydropyridoindole derivatives
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
PH12015500301B1 (en) A novel formulation of diclofenac
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
MX2009009591A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2007110422A3 (en) Whey protein vehicle for active agent delivery
PH12016500746B1 (en) A novel formulation of meloxicam
TW200711719A (en) Use of 2,3-dihydroxynaphthalene-6-sulfonic acid salts as dispersants
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
BR112014000080A8 (pt) dispositivo de reconstituição
TW200800940A (en) New primary amines
HK1123986A1 (en) Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid
UA97496C2 (ru) Композиция укорененных мицеллярных наночастичек и способ ее получения
GB201318380D0 (en) Optimised preparations of highly adaptable aggregates
GR1007770B (el) Φαρμακευτικο σκευασμα περιεχον ρεπαγλινιδη και μεθοδος για την παρασκευη αυτου
EA201100734A1 (ru) Фармацевтическая композиция антибактериального действия для наружного применения, способ ее получения
UA99734C2 (ru) Производные азабифениламинобензойной кислоты как ингибиторы dhodh
CL2008000671A1 (es) Compuestos derivados de 3-ciano-4-(4-tetrahidropiran-fenil)-piridin-2-ona; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ansiedad, migraña, epilepsia, entre otros.
CL2008000672A1 (es) Compuestos derivados de 3-ciano-4-(4-piridiniloxi-fenil)-piridin-2-ona; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ansiedad, migrana, epilepsia, entre otros.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal